Oracle today announced the availability of Oracle® Health Sciences Central Coding Release 3.0. The third generation of the Web-based clinical trial data coding and dictionary management application includes expanded query management and automated workflows that help clinical trial sponsors and contract research organizations (CROs) improve the efficiency and consistency of the coding process.
Oracle Health Sciences Central Coding Release 3.0 features enhanced integration with Oracle Health Sciences InForm Global Trial Management Global Trial Management system, which promotes greater productivity via improved query management and workflow. This release enables users to create and manage Oracle Health Sciences InForm Global Trial Management queries directly in Oracle Health Sciences Central Coding Release 3.0, streamlining the coding process with one point of entry to apply and manage coding updates to all Oracle Health Sciences InForm Global Trial Management-managed trials in process.
It features:
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.